Key result
Mibefradil reduced diastolic and systolic blood pressure compared to placebo, with a significant dose-response relationship.
Why the study?
Does mibefradil reduce blood pressure in patients with mild to moderate hypertension?
RCT (n=202)
Double-blind
parallel group
Yes
Does mibefradil reduce blood pressure in patients with mild to moderate hypertension?
Mibefradil is an effective and well-tolerated antihypertensive compound at doses of 25 to 100 mg once daily, providing significant blood pressure reduction with a favorable trough-peak ratio.
Answers are grounded in this paper and cite their sources.
Supports mibefradil (25-100 mg daily) for mild-moderate hypertension; confirms dose-dependent efficacy in RCT.
Preclinical and initial clinical studies suggest that the novel calcium antagonist mibefradil has a unique combination of properties. Mibefredil was evaluated in a multicenter, double-blind, placebo-controlled, parallel group trial. After 4 weeks of a placebo run-in period, 202 eligible patients with mild to moderate hypertension were randomized to receive doses of 25, 50, 100, or 150 mg mibefradil or placebo once a day for 4 weeks. Blood pressure and heart rate were measured repeatedly at trough and peak (24 and 2 to 6 hours postdose, respectively) at the end of each period. Concentration-effect relationships were evaluated at trough on the last treatment day. A significant (P<.01 versus placebo) drop in blood pressure (diastolic and systolic) was observed at trough and peak in all mibefradil groups, with a trough-peak ratio greater than 0.8, high response rate, and a significant dose-response relationship (P<.001). The full antihypertensive effect of mibefradil was achieved within 1 to 2 weeks and was associated with a slight dose-dependent decrease in heart rate and increase in PQ time. Clear dissociation was observed between the effect on blood pressure and PQ time when concentration-effect relationships were evaluated. These results indicate that mibefradil is an effective and well-tolerated antihypertensive compound at doses of 25, 50, and 100 mg once daily. The incidence of treatment-related adverse events observed in the 25-, 50-, and 100-mg dose groups was lower than in the placebo group, but it was slightly higher in the 150-mg dose group, and three patients from this group were prematurely withdrawn because of an adverse event.
No takes yet. Share an insight, caveat, or question.
Bernink et al. (1996) conducted an RCT in mild to moderate hypertension (n=202). mibefradil vs. placebo was evaluated on drop in blood pressure (diastolic and systolic) (p=<.01). Mibefradil reduced diastolic and systolic blood pressure compared to placebo, with a significant dose-response relationship.
Synapse has enriched 10 related papers. Consider them for comparative context: